Survival benefit from the combination of gemcitabine with paclitaxel and the role of patients’ stratification for FOLFORINOX are investigated in metastatic and locally advanced settings
After TILs have shown benefits in advanced melanoma, many ‘synthetic biology’ strategies can be conceived to potentially extend this clinical signal to other patient groups
Patient-reported data from the DESTINY-BREAST04 and TROPiCS-02 trials may help improve current knowledge of quality of life on long-term treatment
Negative results from the CANOPY-A trial do not support use in the adjuvant setting
Nirogacestat improves progression-free survival in a randomised trial performed in desmoid tumours
In a head-to-head comparison to the standard of care, tumour-infiltrating lymphocytes show clinical efficacy even in patients who are refractory to anti-PD-1 treatment
In a study presented at ESMO Congress 2022, air pollution is shown to drive interleukin-1β release in cells with EGFR mutations to promote lung cancer development
Three studies support the use of NGS to better understand the molecular drivers of this brain tumour, but effective targeted treatments are still lacking
Updated overall survival data from TOPAZ-1 confirm clinically meaningful benefit of adding durvalumab to cisplatin/gemcitabine
Standard second-line chemotherapy may benefit fit patients but efficacy is limited and new treatments are urgently needed
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.